Company News

Galapagos reports progress for CF drug

A new small molecule drug intended to treat cystic fibrosis patients with the F508del gene mutation has been well tolerated in patients in a Phase 2 study, paving the way for its use as part of a triple therapy, Galapagos NV announced on 19 November.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium

Roche has two Phase 3 successes

Roche has reported positive Phase 3 results for two different antibody therapeutics putting it in a leadership position for treating both non-small cell lung cancer and haemophilia A. The cancer trial was significant because it showed the benefits of using a checkpoint inhibitor as part of a triple therapy.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland

Meeting Report: Building the European capital market

What will it take to build an integrated capital market in Europe? This question engaged executives at a BioEurope conference in Berlin on 6 to 8 November. The answer was both short and sweet, and long and complex.

Location

Germany

Ablynx provides nine-month update

Ablynx NV, the Belgian antibody specialist, has released financial results for the first nine months of 2017 which show an operating loss due to significant outlays for research and development, but a strong cash balance. This was later augmented by a successful IPO on US Nasdaq.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium

Partnership seeks in vivo gene editing

Crispr Therapeutics AG and its joint venture with Bayer AG called Casebia Therapeutics LLP have signed an exclusive collaboration agreement with CureVac AG to develop therapeutics that exploit both the new gene editing and messenger RNA (mRNA) technologies.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Switzerland

New drug for CMV after transplants

The European Medicines Agency has recommended a new medicine that can prevent cytomegalovirus (CMV) reactivation and disease in patients who have received an allogeneic stem cell transplant. The medicine, Prevymis (letermovir), was developed by Merck & Co Inc.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Roche MS drug recommended by EMA

A new monoclonal antibody treatment for multiple sclerosis (MS) has been recommended for approval by the European Medicines Agency following clinical studies that showed significant benefits for patients with both relapsing and primary progressive forms of the disease.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Patrick Vallance to become UK chief scientific adviser

Patrick Vallance, head of research and development at GlaxoSmithKline Plc, is to join the UK government as chief scientific adviser at the end of March 2018. The appointment comes as the UK negotiates its departure from the European Union.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Higher operating profit at AZ

AstraZeneca Plc has given a slightly more optimistic forecast for the bottom line this year and expressed confidence about a return to growth, as the last of its legacy products loses patent protection in Europe. The company still expects a decline in core earnings per share, but the fall is expected to be closer to 10% than to a mid-teen percentage decline.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Lundbeck results disappoint, management in transition

Shares of H. Lundbeck A/S, which makes drugs for treating disorders of the central nervous system, closed down 7.3% on 8 November despite the release of favourable results for the third quarter and improved guidance for the year. A concern is the company’s transition to new management. 

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Denmark

Syndicate content